Ve­ra’s $300M of­fer­ing; Abeona re­sub­mits treat­ment for rare skin dis­ease

Plus, news about Astel­las, Clover, El­e­vate­Bio, Monopar, Idor­sia and Neu­ro­crine Bio­sciences:

Ve­ra Ther­a­peu­tics plans $300M of­fer­ing: The Cal­i­for­nia biotech is

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER